ImmunityBio
IBRX
IBRX
64 hedge funds and large institutions have $32.8M invested in ImmunityBio in 2018 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
25% less capital invested
Capital invested by funds: $43.5M → $32.8M (-$10.7M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $18K
Holders
64
Holding in Top 10
–
Calls
–
Puts
$18K
Top Buyers
| 1 | +$668K | |
| 2 | +$391K | |
| 3 | +$306K | |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$288K |
| 5 |
Bank of New York Mellon
New York
|
+$150K |
Top Sellers
| 1 | -$1.45M | |
| 2 | -$1.32M | |
| 3 | -$896K | |
| 4 |
AA
ALPS Advisors
Denver,
Colorado
|
-$414K |
| 5 |
VF
Virtu Financial
New York
|
-$180K |